Rossari BiotechNSE:ROSSARI +1.03%84 PE Ratio (TTM) is 19.48 as of Jul. 11, 2026, which is 48% below its 10-year median of 37.82. GuruFocus rates NSE:ROSSARI with a GF Score™ of 84/100 and a GF Value™ of ₹1,003.68 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,152 Chemicals companies, Rossari Biotech ranks better than 61.11% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-11), Rossari Biotech's share price is
₹524.20.
Rossari Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹26.91. Therefore, Rossari Biotech's PE Ratio (TTM) for today is 19.48.
The historical rank and industry rank for Rossari Biotech's PE Ratio (TTM) or its related term are showing as below:
NSE:ROSSARI'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 15.94 Med: 37.82 Max: 87.46
Current: 18.99
During the past 9 years, the highest PE Ratio (TTM) of Rossari Biotech was 87.46. The lowest was 15.94. And the median was 37.82.
NSE:ROSSARI's PE Ratio (TTM) is ranked better than 61.11% of 1152
companies
in the Chemicals industry
Industry Median: 24.695
vs NSE:ROSSARI: 18.99
During the past 12 months, Rossari Biotech's average EPS without NRIGrowth Rate was -0.70% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 8.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 10.70% per year.
During the past 9 years, Rossari Biotech's highest 3-Year average EPS without NRI Growth Rate was 42.10% per year. The lowest was 8.00% per year. And the median was 14.20% per year.
Rossari Biotech's EPS (Basic) for the
three
months ended in Mar. 2026 was ₹8.30.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹26.95.
Rossari Biotech (NSE:ROSSARI) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Rossari Biotech PE Ratio (TTM) Related Terms
Rossari Biotech PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Rossari Biotech's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ROSSARI vs LIN, SHW, ECL: PE Ratio (TTM) Comparison
For the Specialty Chemicals subindustry, Rossari Biotech's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rossari Biotech PE Ratio (TTM) vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Rossari Biotech's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Rossari Biotech's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Rossari Biotech's Share Price of today is ₹524.20.
Rossari Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹26.91.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Rossari Biotech (NSE:ROSSARI) has a PE Ratio (TTM) of 19.48 as of Jul. 11, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Rossari Biotech and its competitors. This is 48% below median its historical median of 37.82. Over the past decade, Rossari Biotech's PE Ratio (TTM) has ranged from 15.94 to 87.46. According to the industry distribution chart, Rossari Biotech ranks #448 out of 1152 companies in the Chemicals industry, placing it in the top 38.9%.
Is Rossari Biotech's PE Ratio (TTM) too high?
Rossari Biotech's current PE Ratio (TTM) of 19.48 is 48% below median its 10-year median of 37.82. Over the past 10 years, this metric has ranged from a low of 15.94 to a high of 87.46. The Chemicals industry median PE Ratio (TTM) is 24.70. Rossari Biotech's value of 19.48 is 21.1% below this industry median. Based on the distribution chart, Rossari Biotech ranks #448 out of 1152 companies in the Chemicals industry, which is above the industry midpoint. Overall, Rossari Biotech has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rossari Biotech's PE Ratio (TTM) compare to LIN and SHW?
According to the Chemicals industry distribution chart, Rossari Biotech ranks #448 out of 1152 companies for PE Ratio (TTM). This puts Rossari Biotech in the upper half of its industry. The industry median PE Ratio (TTM) is 24.70. Rossari Biotech's value of 19.48 is 21.1% below this benchmark. Historically, Rossari Biotech's own PE Ratio (TTM) has ranged from 15.94 to 87.46 over the past decade. While the company's 10-year median is 37.82 vs. the industry median of 24.70, Rossari Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Chemicals company?
The median PE Ratio (TTM) among Chemicals companies is 24.70, based on 1,152 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rossari Biotech's current PE Ratio (TTM) of 19.48 is 21.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Rossari Biotech and its competitors. For the Chemicals industry, the median PE Ratio (TTM) is 24.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rossari Biotech's current PE Ratio (TTM) is 19.48, which is 48% below median its own 10-year median of 37.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rossari Biotech stock overvalued right now?
Based on GuruFocus' analysis, Rossari Biotech (NSE:ROSSARI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1,003.68, compared to a current price of ₹524.20 — trading 47.8% below its estimated fair value. The current PE Ratio (TTM) is 19.48, which is 48% below median its 10-year median of 37.82 and 21.1% below the Chemicals industry median of 24.70. Rossari Biotech's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Rossari Biotech (NSE:ROSSARI), the current PE Ratio (TTM) is 19.48 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rossari Biotech (NSE:ROSSARI) Overvalued in 2026?
Based on GuruFocus' analysis, Rossari Biotech stock appears to be undervalued.
The current stock price of ₹524.20 is trading 47.8% below its estimated GF Value™ of ₹1,003.68.
GuruFocus considers Rossari Biotech to be Possible Value Trap.
Key valuation signals for NSE:ROSSARI:
PE Ratio (TTM): 19.48 (48% below median its 10-year median of 37.82)
GF Value™: ₹1,003.68 vs. price of ₹524.20 (47.8% below fair value)
Industry Position: 21.1% below the Chemicals median (#448 of 1152)
No single metric tells the full story. See the NSE:ROSSARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rossari Biotech Ltd is a specialty chemical manufacturing company. It provides customized solutions to specific industrial and production requirements of its customers in the FMCG, apparel, poultry, and animal feed industries through its product portfolio comprising home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its business is organized into three categories: home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its products include soaps and detergents, paints, inks and coatings, ceramics and tiles, water treatment chemicals, pulp and paper, and cleaning chemical formulations, among others. The company generates the majority revenue from India.
84GF Score
Get the complete analysis for NSE:ROSSARI
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ROSSARI has been successfully added to your 
